Compare IMXI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | ANAB |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.2M | 1.2B |
| IPO Year | N/A | 2017 |
| Metric | IMXI | ANAB |
|---|---|---|
| Price | $15.35 | $48.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $16.67 | ★ $59.90 |
| AVG Volume (30 Days) | 241.4K | ★ 516.9K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $625,123,000.00 | $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | $0.95 | N/A |
| P/E Ratio | $11.91 | ★ N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $8.58 | $12.21 |
| 52 Week High | $21.41 | $49.90 |
| Indicator | IMXI | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 75.12 |
| Support Level | $15.35 | $43.92 |
| Resistance Level | $15.51 | $47.86 |
| Average True Range (ATR) | 0.06 | 2.36 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 39.62 | 88.43 |
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).